BRCA2 is one of the most important DNA repair genes in the human genome, encoding a 3,418-amino acid protein that orchestrates homologous recombination¹¹ homologous recombination
The high-fidelity DNA repair pathway that uses a sister chromatid as a template to accurately repair double-strand breaks; BRCA2's primary role is loading RAD51 onto single-stranded DNA at break sites repair of double-strand DNA breaks. Pathogenic mutations that severely disrupt BRCA2 function carry lifetime breast cancer risks of 45-70% and ovarian cancer risks of 10-20%. The K3326X variant is fundamentally different: it creates a premature stop codon that truncates only the last 93 amino acids of the protein, leaving the core DNA repair domains intact. This distinction matters enormously for how carriers should understand their results.

The Mechanism

The c.9976A>T substitution converts lysine at position 3326 to a stop codon, truncating the final 93 residues of BRCA2. This C-terminal region contains the last four residues of a RAD51 binding domain²² RAD51 binding domain
RAD51 is the recombinase enzyme that BRCA2 loads onto single-stranded DNA at double-strand break sites; the C-terminal binding site is one of multiple RAD51 interaction interfaces on BRCA2, a nuclear localization signal, and a phosphorylation site at Thr3387³³ Thr3387
A threonine residue phosphorylated by CDK2; its loss may subtly alter cell cycle-dependent regulation of BRCA2 nuclear import. Critically, the eight central BRC repeats⁴⁴ BRC repeats
The primary RAD51-binding motifs (BRC1-BRC8) spanning residues 1002-2085, which are the main functional interface for loading RAD51 onto damaged DNA, the DNA binding domain, and the tower domain⁵⁵ tower domain
A helical structure within the DNA binding domain that directly contacts double-stranded DNA are all preserved.

The truncated protein is expressed at normal transcript levels and retains substantial homologous recombination activity. This explains why K3326X does not behave like classic pathogenic BRCA2 mutations: the protein is partially functional, not absent. The residual impairment appears to reduce repair efficiency enough to measurably increase cancer risk — particularly for cancers driven by environmental genotoxic exposures — without the catastrophic loss of function seen in frameshift or early truncation mutations.

The Evidence

The definitive epidemiological study came from the iCOGS consortium⁶⁶ iCOGS consortium
Meeks HD et al. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. JNCI, 2015, analyzing 76,637 cancer cases and 83,796 controls. K3326X carriers showed an OR of 1.28 (95% CI: 1.17-1.40) for breast cancer overall, rising to 1.46 for estrogen receptor-negative breast cancer and 1.50 for triple-negative breast cancer. Ovarian cancer risk was elevated at OR 1.26 (95% CI: 1.10-1.43), strongest for the serous subtype. Prostate cancer showed no significant association. Importantly, these associations were independent of other pathogenic BRCA2 variants.

For lung cancer, Wang et al.⁷⁷ Wang et al.
Wang Y et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nature Genetics, 2014 identified K3326X as one of the strongest rare-variant associations in lung cancer genetics: OR 2.47 (P = 4.74 x 10^-20) for squamous cell lung cancer in a study of 21,594 cases and 54,156 controls. A subsequent Icelandic/Dutch study⁸⁸ Icelandic/Dutch study
Rafnar T et al. Association of BRCA2 K3326* With Small Cell Lung Cancer and Squamous Cell Cancer of the Skin. JNCI, 2018 extended this to small cell lung cancer (OR 2.06) and squamous cell skin cancer (OR 1.69), noting that K3326X associates primarily with cancers driven by environmental genotoxic exposures.

Martin et al.⁹⁹ Martin et al.
Martin ST et al. Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene, 2005 first flagged K3326X as functionally relevant, finding it in 5.6% of familial pancreatic cancer patients versus 1.2% of controls (OR 4.84). A comprehensive review¹⁰¹⁰ comprehensive review
Baughan S and Tainsky MA. K3326X and Other C-Terminal BRCA2 Variants Implicated in Hereditary Cancer Syndromes: A Review. Cancers, 2021 synthesized these findings, concluding that K3326X confers moderate risk increases across multiple cancer types, particularly those with strong environmental genotoxic components.

Practical Implications

K3326X carriers should understand two critical points. First, this is NOT a pathogenic BRCA2 mutation. It does not qualify for BRCA clinical management pathways such as prophylactic mastectomy or oophorectomy, risk-reducing salpingectomy, or PARP inhibitor eligibility. The moderate risk elevations (OR 1.2-1.5 for breast and ovarian cancer) are in a fundamentally different category from pathogenic BRCA2 mutations (lifetime risks of 45-70% for breast cancer).

Second, the risk pattern is real and actionable at the screening level. Enhanced breast cancer surveillance with supplemental imaging (breast MRI in addition to mammography) is a proportionate response for female carriers, particularly given the stronger association with ER-negative and triple-negative subtypes that mammography detects less reliably. For lung cancer, the substantially elevated risk (OR 2.47 for squamous cell) makes low-dose CT screening worth discussing with a physician, especially for carriers with any smoking history.

Interactions

K3326X sits in the broader context of DNA repair and cancer susceptibility. Carriers who also carry variants in other DNA repair pathway genes — such as ATM (rs1801516), CHEK2, or TP53 (rs1042522) — may have compounded impairment of genomic integrity maintenance. The Wang et al. 2014 study notably identified CHEK2 I157T (rs17879961) alongside K3326X as a large-effect lung cancer variant, suggesting these DNA damage checkpoint and repair pathways interact in determining cancer susceptibility. However, formal gene-gene interaction studies for K3326X combinations remain limited, and compound action recommendations should await stronger evidence.

Deep inside your brain, the thalamus acts as a sensory relay station — filtering and routing signals between your body and cortex throughout the day, and shifting into a dampened state that allows sleep at night. In restless legs syndrome (RLS), this relay appears to malfunction: something keeps it overstimulated at exactly the moment it should be going quiet. GRIA1 encodes the GluA1 subunit of the AMPA receptor¹¹ GRIA1 encodes the GluA1 subunit of the AMPA receptor
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors are the principal fast excitatory receptors in the brain, responsible for most rapid synaptic transmission, the most abundant fast-excitatory glutamate receptor in the central nervous system. A variant within this gene — rs10038916 — has now been genome-wide significantly associated with RLS risk, implicating glutamatergic hyperactivity as a core biological mechanism.

The Mechanism

rs10038916 is an intronic variant at position 153,718,534 on chromosome 5 (GRCh38), within GRIA1. It does not change the GRIA1 protein sequence directly, but intronic variants at GWAS significance typically act through regulatory effects: altering splicing patterns, enhancer activity, or expression levels of the gene in specific tissues. Elevated GRIA1 activity in thalamic circuits would increase glutamate-mediated excitatory transmission at exactly the circuits implicated in arousal.

MR spectroscopy studies have directly measured thalamic glutamate and glutamine (collectively Glx) in people with RLS and found it significantly elevated compared to controls — a Glx/creatinine ratio of 1.20 ± 0.73 versus 0.80 ± 0.39 (t=2.2, p=0.016)²² MR spectroscopy studies have directly measured thalamic glutamate and glutamine (collectively Glx) in people with RLS and found it significantly elevated compared to controls — a Glx/creatinine ratio of 1.20 ± 0.73 versus 0.80 ± 0.39 (t=2.2, p=0.016). Critically, this elevation correlated strongly with the degree of sleep disruption (r=0.61, p=0.007) but not with periodic leg movements, pointing toward glutamate as the driver of the arousal and sensory components of RLS rather than the motor component. This dissociation has mechanistic implications: it suggests the unpleasant sensations and inability to sleep that define RLS symptomatically may be governed by glutamatergic circuitry, while the leg-movement aspect may be more dopamine-driven.

The upstream trigger for this glutamate excess is brain iron deficiency³³ brain iron deficiency
even when serum iron is normal, the brain can be iron-deficient; this is measurable via ferritin in cerebrospinal fluid and correlates strongly with RLS severity. Iron is a cofactor for tyrosine hydroxylase and for adenosine synthesis; when brain iron falls, dopaminergic tone drops and the adenosine-mediated inhibitory brake on glutamate release weakens simultaneously. The result is a hyperglutamatergic state in cortico-striatal-thalamic circuits⁴⁴ hyperglutamatergic state in cortico-striatal-thalamic circuits — exactly the circuits where GRIA1 is most abundantly expressed. Individuals who carry the G allele at rs10038916 may have somewhat higher GRIA1 activity at baseline, making thalamic glutamate dysregulation easier to trigger and harder to compensate for.

Animal studies reinforce the link: complete deletion of the Gria1 gene in mice produces fragmented, misaligned rest-activity patterns, attenuated light-induced sleep suppression, and heightened but erratic responses to environmental cues⁵⁵ complete deletion of the Gria1 gene in mice produces fragmented, misaligned rest-activity patterns, attenuated light-induced sleep suppression, and heightened but erratic responses to environmental cues. This parallels the RLS phenotype of disrupted nocturnal sleep with increased arousal sensitivity, suggesting GRIA1 is not just a statistical hit in a GWAS but a biologically plausible node in the RLS circuit.

The Evidence

The central evidence comes from the largest RLS GWAS ever conducted⁶⁶ largest RLS GWAS ever conducted: a meta-analysis by Schormair, Zhao, Bell and colleagues (2024, Nature Genetics) pooling 116,647 individuals with RLS and 1,546,466 controls of European ancestry. This study multiplied the number of known RLS risk loci eightfold — from roughly 20 to 164. Among these 164 loci, rs10038916 at GRIA1 reached p=9.99×10⁻¹⁶, far beyond the standard genome-wide significance threshold of 5×10⁻⁸. The paper specifically highlighted GRIA1 and the related glutamate receptor gene GRIA4 as "druggable" targets, meaning they encode proteins for which modulatory compounds already exist or can be developed. This is only the second time glutamate receptor genetics have been implicated in RLS at genome-wide significance — the identification of two independent GWAS hits in AMPA receptor genes argues strongly for a genuine glutamatergic contribution to RLS biology rather than a statistical artifact.

The study also found that genetic risk factors for RLS overlap with genetic predispositions to diabetes (Mendelian randomization identified RLS as a causal risk factor for diabetes), and that sex-specific analyses showed largely overlapping genetic architecture (rg=0.96 between sexes), meaning rs10038916 is equally relevant in men and women. RLS affects approximately 5–10% of adults of European descent and is substantially heritable, with the Schormair 2024 data representing the definitive genetic architecture to date.

The G allele at rs10038916 is the minor allele in Europeans (~34%) and nearly absent in East Asians (~4%), aligning with known epidemiological observations that RLS prevalence is higher in Europeans than in East Asian populations.

Practical Implications

The genetic association points toward brain iron availability and glutamate regulation as the two modifiable targets most relevant to your genotype. Non-pharmacological approaches to RLS with glutamatergic rationale include iron optimization (brain iron deficiency is the upstream trigger for the hyperglutamatergic state) and careful attention to anything that further elevates thalamic glutamate at night — including some medications and dietary factors. Gabapentin and pregabalin, the leading non-dopaminergic drug treatments for RLS, work through α2δ calcium channel subunits that reduce presynaptic neurotransmitter release including glutamate, which may explain why they specifically address the sensory/arousal component that correlates with thalamic Glx elevation.

RLS has long been managed primarily with dopamine agonists, but the Schormair 2024 findings strengthen the scientific case for glutamate-targeting alternatives — an important development given that dopamine agonists cause augmentation (worsening symptoms) in up to 50% of long-term users.

Interactions

The most directly relevant interaction is with rs10895816 at GRIA4 — a second AMPA receptor subunit gene that also reached genome-wide significance in the same Schormair 2024 GWAS meta-analysis. GRIA1 and GRIA4 encode two of the four GluA subunits that assemble into functional AMPA receptor tetramers; variants in both genes affecting receptor properties or expression would be expected to have compounding effects on glutamatergic excitability in thalamic circuits. Users who carry the risk allele at both rs10038916 (GRIA1) and rs10895816 (GRIA4) may have a stronger glutamatergic signature than either variant alone would produce, though the combined effect has not been quantified separately in published studies.

Your immune system runs a continuous quality-control operation inside every cell. Proteins are constantly degraded, and small fragments — peptides — are trimmed to the correct 8-10 amino acid length¹¹ trimmed to the correct 8-10 amino acid length
a precisely sized peptide is required for stable binding to MHC class I molecules on the cell surface; peptides that are too long or too short cannot bind and are discarded by ERAP1 (Endoplasmic Reticulum Aminopeptidase 1) before being loaded onto HLA class I display platforms. This curated peptide sample is then presented on the cell surface for inspection by patrolling CD8+ T cells — the checkpoint that determines whether a cell is "self" or dangerous.

The D575N variant changes a single amino acid in ERAP1's catalytic domain. This substitution does not knock out the enzyme, but it measurably alters trimming efficiency — and in individuals carrying the HLA-B27 antigen, those alterations compound into a meaningful shift in ankylosing spondylitis risk. D575N's effect is context-dependent: it acts synergistically with the more powerful K528R variant (rs30187) to define one of the most well-characterized ERAP1 risk haplotypes in human genetics.

The Mechanism

ERAP1's catalytic domain contains a zinc-active site that cleaves amino acids from the N-terminus of precursor peptides. Position 575 lies within this domain, and the Asp575 residue (C allele) engages in electrostatic interactions that influence the geometry of the active site. The D575N substitution — replacing the negatively charged aspartic acid with the neutral asparagine — subtly perturbs these interactions.

Biochemical characterization of naturally occurring ERAP1 variants shows that Asp575 confers modestly lower trimming activity compared to Asn575, but critically, the magnitude of this effect depends strongly on residue 528 (the K528R variant, rs30187). Functional epistasis studies²² Functional epistasis studies
Evnouchidou et al. 2014: combined effects of ankylosing spondylitis-associated ERAP1 polymorphisms outside the catalytic and peptide-binding sites on the processing of natural HLA-B27 ligands. J Biol Chem, 2014 established the activity hierarchy: Arg528/Asp575 < Lys528/Asp575 < Arg528/Asn575 < Lys528/Asn575. In this ordering, the D (Asp575, C allele at rs10050860) combination with K528 (the rs30187 risk allele) produces the highest enzymatic activity — paradoxically, the risk combination for AS.

This apparent paradox is explained by the nature of ERAP1's role in HLA-B27 biology. HLA-B27 is unusual among HLA class I alleles: it preferentially presents longer, arginine-terminated peptides. ERAP1 over-trimming of HLA-B27 ligands can generate a mis-edited peptide repertoire that triggers autoimmune T cell responses and/or drives HLA-B27 heavy chain misfolding and endoplasmic reticulum stress. Both high-activity and low-activity ERAP1 allotypes can create pathogenic peptide landscapes depending on the specific HLA alleles present.

The Evidence

ERAP1 haplotype and AS susceptibility. The foundational haplotype study by Evans et al. 2009³³ Evans et al. 2009
Association of a specific ERAP1/ARTS1 haplotype with disease susceptibility in ankylosing spondylitis. Arthritis Rheum, 2009 identified a three-SNP haplotype — rs27044/rs10050860/rs30187 coded as CCT — as strongly associated with increased AS risk (pooled OR=1.81, 95% CI 1.46-2.24, P=7×10⁻⁸ across three Canadian cohorts). The rs10050860 C allele (Asp575) is the risk allele in this haplotype. The complementary protective haplotype (rs27044/rs26618/rs30187-CTG, OR=0.77) confirmed the directionality.

Meta-analytic confirmation. A meta-analysis combining 8,530 AS cases and 12,449 controls found that the rs10050860 T allele (Asn575) was significantly protective against AS in European populations, with an OR=0.724 (95% CI 0.665-0.787, P<1×10⁻¹⁰)⁴⁴ OR=0.724 (95% CI 0.665-0.787, P<1×10⁻¹⁰)
Associations between ERAP1 polymorphisms and ankylosing spondylitis susceptibility: a meta-analysis. Arthritis Care Res, 2011. This protective effect is among the strongest individual ERAP1 SNP associations documented, second only to rs30187 in European-ancestry studies.

A PNAS 2017 analysis⁵⁵ PNAS 2017 analysis
ERAP1 association with AS is attributable to common genotypes rather than rare haplotype combinations confirmed that rs10050860 contributes to common genotype combinations that account for the bulk of the ERAP1-AS association, and that the effect is not driven by rare haplotypes. D575N (along with K528R) defines the most prevalent risk and protective ERAP1 genotype classes in the population.

Co-protective state with rs30187. When both rs10050860 T (Asn575) and rs30187 C (Lys528) are inherited together, the combined protective effect on AS risk is substantial. In HLA-B27-positive individuals, this double-protective state reduces AS risk approximately 3-4 fold⁶⁶ this double-protective state reduces AS risk approximately 3-4 fold
Evans et al. 2011: HLA-B27-positive individuals homozygous for protective ERAP1 alleles had substantially lower AS risk than those carrying risk alleles at either or both ERAP1 loci. Nat Genet, 2011. This co-protective effect is functionally grounded: inheriting low-activity alleles at both key positions (528 and 575) produces an ERAP1 enzyme whose trimming kinetics minimally disturb the HLA-B27 peptide repertoire.

Functional ranking. Proteomics-level studies of ERAP1 variant combinations showed that while K528R (rs30187) is the dominant contributor to HLA-B27 peptidome shaping, D575N amplifies the K528R effect and independently contributes to reduced trimming efficiency. Ranking studies⁷⁷ Ranking studies
Kochan et al. 2018, ranking the contribution of AS-associated ERAP1 polymorphisms to shaping the HLA-B27 peptidome noted that D575N's contribution to the HLA-B27 peptidome changes — while smaller than K528R's — is consistently directional and adds to the overall allotype effect.

Important caveat on independent effect. A subset of the rs10050860 signal may be attributable to strong linkage disequilibrium with a nearby splice-altering variant, rs7063, which influences ERAP1 protein levels rather than catalytic function. This does not invalidate the D575N finding — the functional studies above directly demonstrate biochemical effects — but it means the full AS association magnitude at this locus may reflect a combination of coding and regulatory mechanisms.

Practical Implications

Carrying the C allele at rs10050860 (Asp575) means your ERAP1 trimming activity at this position is at the population baseline or slightly higher. On its own, this does not cause disease. The clinical significance of this variant is nearly entirely contingent on your HLA-B27 status and on your rs30187 genotype.

If you carry HLA-B27, the C allele at rs10050860 (particularly if combined with the T allele at rs30187) represents the risk configuration — the ERAP1 allotype that most strongly shifts the HLA-B27 peptidome toward arthritogenic states. Early recognition of ankylosing spondylitis symptoms matters: the disease is effectively managed with NSAIDs and biologics when caught early, but causes irreversible spinal fusion when untreated for years.

If you are homozygous TT at rs10050860, your Asn575 ERAP1 contributes to reduced enzymatic activity. When combined with the CC genotype at rs30187 (Lys528), this double-protective state confers substantially reduced AS risk compared to the risk haplotype.

Interactions

rs10050860 × rs30187 (K528R): Same-gene functional epistasis. The effects of D575N and K528R are not additive — they interact. The activity hierarchy depends on the combination of residues at both positions. Asp575+Lys528 is higher-activity than either protective combination; Asn575+Arg528 is the lowest-activity, most protective allotype for AS. This interaction is the strongest rationale for analyzing both variants together in a compound action context.

rs10050860 × HLA-B27: Disease-determining epistasis. Like all ERAP1 coding variants, D575N's contribution to AS risk operates exclusively through its interaction with HLA-B27. In HLA-B27-negative individuals, the C vs T genotype at rs10050860 has no meaningful AS association. The clinical weight of this variant should be interpreted entirely in the context of HLA-B27 status.

rs10050860 in the ERAP1 haplotype system. ERAP1 has been catalogued into 10+ naturally occurring haplotypes (Hap1-Hap10) defined by combinations of variants including rs30187, rs10050860, rs27044, rs27524, and others. The predominant risk haplotype (MKDRQ: Met349-Lys528-Asp575-Arg725-Gln730) is defined partly by D (Asp575, rs10050860 C allele). The predominant protective haplotype (VRNQE) carries N575 (rs10050860 T allele). Haplotype-level analysis provides a more complete picture than individual SNP analysis for ERAP1 allotype classification.

While rs2052129 affects how much DAO enzyme your body makes, the Thr16Met ¹¹ Threonine to methionine at position 16 variant (rs10156191) changes the actual structure of the enzyme protein. This is a missense mutation ²² A missense mutation changes one amino acid to another in the resulting protein that substitutes threonine with methionine at position 16, potentially altering the enzyme's ability to bind and degrade histamine.

The Mechanism

The amino acid change at position 16 occurs in a region of the protein that influences its folding and copper-binding ability. DAO is a copper-dependent enzyme ³³ DAO requires copper ions at its active site to catalyze the oxidation of histamine, and structural changes near the active site can reduce catalytic efficiency. The T allele produces an enzyme that is less effective at breaking down histamine, even when produced in normal quantities. Ayuso et al.⁴⁴ Ayuso et al.
Ayuso P et al. Genetic variability of human diamine oxidase. Pharmacogenet Genomics, 2007 found that carriers of the variant allele had reduced serum DAO activity compared to non-carriers.

Clinical Significance

This variant is frequently studied alongside other AOC1 variants to determine overall DAO haplotype status. Research by Maintz et al.⁵⁵ Maintz et al.
Maintz L & Novak N. Histamine and Histamine Intolerance. Am J Clin Nutr, 2007 and others has shown that carrying multiple DAO risk variants (across rs2052129, rs10156191, and rs1049793) has an additive effect on reducing enzyme activity. An individual who is heterozygous ⁶⁶ Heterozygous means carrying one normal and one variant copy of a gene at all three positions may have more impaired DAO function than someone who is homozygous at just one. The variant is notably more common in African populations (T allele ~51%) compared to East Asian populations (~11%).

What This Means for You

If you carry the T allele here, evaluate your overall DAO status by considering all three AOC1 variants together. Mild impairment at one position can often be compensated, but compound impairment across multiple variants may tip the balance toward clinically meaningful histamine intolerance. Practical dietary strategies remain the same: fresh foods, low-histamine choices, and DAO supplements with meals if needed.

Endometriosis — where endometrial-like tissue grows outside the uterus — affects an estimated 10% of reproductive-age women and is driven as much by immune dysfunction as by hormonal disruption. This variant sits within a dense inflammatory gene cluster on chromosome 2q13 that encodes six members of the interleukin-1 family¹¹ interleukin-1 family
IL-1 is a family of pro-inflammatory cytokines that coordinate immune responses and tissue remodelling, including IL-1 alpha (IL1A) and IL-1 beta (IL1B). Genetic variation here has been consistently linked to endometriosis risk across diverse populations.

The Mechanism

The rs10167914 variant does not change an amino acid; it sits in the regulatory landscape surrounding IL1A and IL1B and influences how much IL-1 alpha the body produces in peritoneal tissue. The G allele is associated with higher local IL-1 alpha expression. IL-1 alpha, in turn, directly stimulates matrix metalloproteinase-1 (MMP-1)²² matrix metalloproteinase-1 (MMP-1)
an enzyme that breaks down the extracellular matrix, enabling ectopic cells to invade surrounding tissue, recruits inflammatory cells to the peritoneum, and sustains the chronic low-grade inflammation that allows endometriotic implants to establish, survive, and proliferate. G-allele carriers thus have a molecular environment more permissive to lesion growth — not through oestrogen alone, but through an IL-1-mediated inflammatory loop.

The Evidence

The strongest signal comes from a large meta-analysis by Sapkota et al.³³ meta-analysis by Sapkota et al.
Sapkota Y et al. Meta-analysis identifies five novel loci associated with endometriosis highlighting key genes involved in hormone metabolism. Nat Commun, 2017 combining 17,045 endometriosis cases with 191,596 controls. rs10167914-G reached p=1×10⁻⁹ with an odds ratio of 1.12 (95% CI 1.08–1.15), a replicable, genome-wide-significant effect. An earlier targeted study Sapkota et al. 2015⁴⁴ Sapkota et al. 2015
Sapkota Y et al. Association between endometriosis and the interleukin 1A (IL1A) locus. Hum Reprod, 2015 confirmed IL1A locus signals in both European (3,908 cases) and Japanese samples, with rs6542095 reaching OR 1.21 for moderate-to-severe disease.

A detailed functional analysis by Gajbhiye et al. 2018⁵⁵ Gajbhiye et al. 2018
Gajbhiye R et al. Genetic Variation at Chromosome 2q13 and Its Potential Influence on Endometriosis Susceptibility Through Effects on the IL-1 Family. Reprod Sci, 2018 mapped the 500 kb region around rs10167914 and found that the locus spans 21 transcripts including six IL-1 family genes, supporting a regulatory role whereby risk variants alter expression across this entire cytokine network rather than affecting a single gene.

Protein-level confirmation comes from Hudelist et al. 2005⁶⁶ Hudelist et al. 2005
Hudelist G et al. Interleukin 1alpha and tissue-lytic MMP-1 are elevated in ectopic endometrium. Hum Reprod, 2005: IL-1 alpha staining was significantly higher in endometriotic lesions than in matched eutopic endometrium (p<0.001), with co-expression of MMP-1, the matrix-degrading enzyme it induces.

Practical Actions

For women carrying one or two G alleles, the actionable terrain involves managing IL-1 pathway activity and reducing the peritoneal inflammatory load. Long-chain omega-3 fatty acids (EPA and DHA) downregulate IL-1 alpha production by shifting eicosanoid biosynthesis toward less pro-inflammatory prostaglandins. This is a mechanism-specific intervention, not generic anti-inflammatory advice — the same shift does not occur with short-chain ALA from plant oils.

In clinical settings, IL-1 receptor antagonism (anakinra, canakinumab) is being explored for endometriosis. Women with confirmed or suspected endometriosis who carry the G allele have a biological rationale to discuss IL-1 pathway modulation with a specialist, particularly if standard hormonal therapies have been inadequate.

Monitoring pelvic pain patterns and dysmenorrhea severity is warranted: the same locus reaches genome-wide significance for dysmenorrhea in a Japanese GWAS by Hirata et al. 2018⁷⁷ Japanese GWAS by Hirata et al. 2018
Hirata T et al. A genome-wide association study of endometriosis in Japanese women. J Hum Genet, 2018, suggesting IL-1 pathway variants also modulate menstrual pain independently of visible lesions.

Interactions

The IL1A locus does not operate in isolation. IL-1 alpha signalling amplifies oestrogen- driven lesion survival — rs10167914-G carriers who also carry variants reducing oestrogen catabolism (e.g. CYP1B1 or CYP19A1 variants) may face a compounded inflammatory-hormonal milieu. Similarly, variants affecting NF-κB activation (TNF-α locus, NFKB1) or the prostaglandin pathway (PTGS2/COX-2) share mechanistic overlap with IL-1 signalling in endometriotic tissue. No compound action is proposed here — these interactions require dedicated literature support rather than pathway inference alone.

The connection between salt and blood pressure is not the same for everyone. For about a quarter of the population, sodium intake triggers a pronounced rise in blood pressure — what researchers call salt sensitivity¹¹ salt sensitivity
a phenotype where blood pressure changes by 5 mmHg or more between high- and low-sodium diets. The SLC4A5 gene — encoding NBCe2, the sodium bicarbonate cotransporter type 2²² NBCe2, the sodium bicarbonate cotransporter type 2
a membrane protein that moves one sodium ion alongside three bicarbonate ions from the kidney tubule lumen into the bloodstream — sits at the heart of this individual variation. rs10177833 is an intronic variant in SLC4A5 with one of the largest effect sizes ever identified for salt-sensitive blood pressure.

The Mechanism

NBCe2 is expressed in the proximal tubule of the kidney³³ proximal tubule of the kidney
the first segment of the nephron, responsible for reabsorbing the bulk of filtered sodium, bicarbonate, glucose, and amino acids. Under normal conditions, NBCe2 recovers bicarbonate alongside sodium from the tubular fluid — a process essential for acid-base balance. The A allele at rs10177833 alters this transporter's activity in a direction that promotes sodium retention.

Cell biology experiments showed that renal proximal tubule cells carrying the variant (A allele at rs10177833 and rs7571842) exhibited significantly increased luminal-to-basolateral sodium transport, elevated NHE3 protein expression, and faster bicarbonate-dependent pH recovery⁴⁴ renal proximal tubule cells carrying the variant (A allele at rs10177833 and rs7571842) exhibited significantly increased luminal-to-basolateral sodium transport, elevated NHE3 protein expression, and faster bicarbonate-dependent pH recovery
compared to wild-type cells carrying the C allele. This gain-of-function pushes more sodium back into the circulation — the same net effect as eating more salt, but driven by genotype rather than diet. Animal data support the clinical direction: SLC4A5 knockout mice develop persistent arterial hypertension⁵⁵ SLC4A5 knockout mice develop persistent arterial hypertension
because loss of normal bicarbonate reabsorption triggers compensatory sodium retention through alternative transporters, and SLC4A5-deficient mice show upregulated epithelial sodium channel (ENaC) activity in the distal tubule⁶⁶ SLC4A5-deficient mice show upregulated epithelial sodium channel (ENaC) activity in the distal tubule
further amplifying sodium retention and blood pressure elevation.

The Evidence

The pivotal human study was a randomized controlled trial of 185 white adults⁷⁷ randomized controlled trial of 185 white adults
each consuming 7-day low-sodium (10 mmol/day) and 7-day high-sodium (300 mmol/day) diets in randomized sequence by Carey et al. at the University of Virginia. rs10177833 showed a highly significant association with salt sensitivity (P=3.1×10⁻⁴) with an odds ratio of 0.221 for the protective C allele⁸⁸ highly significant association with salt sensitivity (P=3.1×10⁻⁴) with an odds ratio of 0.221 for the protective C allele
meaning carriers of the C allele were roughly 4-5 times less likely to be salt-sensitive compared to A/A homozygotes. The result survived adjustment for BMI and age (adjusted OR 0.286, P=2.6×10⁻⁴) and was confirmed in a second independent cohort; meta-analysis across both cohorts yielded P=1.1×10⁻⁴⁹⁹ meta-analysis across both cohorts yielded P=1.1×10⁻⁴
one of the strongest genetic associations for salt sensitivity reported to date.

An experimental study in immortalized human renal proximal tubule cells¹⁰¹⁰ experimental study in immortalized human renal proximal tubule cells
using lines derived from individuals genotyped at rs10177833 mechanically confirmed the functional consequence of the A allele: increased NBCe2 mRNA and protein expression, and enhanced sodium transport activity. A community study of 137 African American women¹¹¹¹ 137 African American women
from the Midwestern United States found that rs10177833 interacted with skin tone to predict systolic blood pressure (P=0.0153), and a study of 20 normotensive subjects¹²¹² 20 normotensive subjects
monitored for salt intake and taste perception found A-allele carriers consumed significantly more sodium (P=0.037), suggesting genotype may also shape dietary behavior around salt.

Practical Actions

The A/A genotype marks a physiological state where the kidneys retain more sodium per gram ingested. Standard dietary salt guidelines (typically <2,300 mg sodium per day for adults) were set for the general population — but A/A carriers likely benefit from more aggressive targets. The evidence from the Carey et al. RCT used a very low-sodium protocol (10 mmol/day, roughly 230 mg sodium) for comparison, illustrating how dramatic the blood pressure response can be at extremes of sodium intake.

Because NBCe2 is a renal transporter, interventions that target sodium balance — sodium restriction, monitoring urinary sodium excretion, and blood pressure tracking during dietary changes — are the most evidence-aligned responses. There is no pharmacogenomic guideline for SLC4A5, but the mechanistic overlap with renal sodium-handling suggests that sodium-sensitive antihypertensives (thiazide diuretics, low-sodium DASH-style diets) may be particularly effective. Confirming salt sensitivity through a clinical blood pressure challenge (measuring response to sodium loading and restriction) can quantify individual responsiveness and guide treatment intensity.

Interactions

rs10177833 co-occurs and interacts functionally with rs7571842¹³¹³ rs7571842
another intronic SLC4A5 variant that independently tags salt-sensitive blood pressure in the same genetic region. Both variants were tested in the Carey et al. cohort and showed nearly identical p-values and odds ratios; the Gildea et al. cell study examined both together. A compound heterozygote carrying risk alleles at both loci may have additive upregulation of NBCe2 transport activity, though formal interaction analysis across both genotypes has not been published.

Where your body stores fat matters as much as how much fat you carry. Two people with identical BMI can have entirely different metabolic risk profiles depending on whether their excess fat accumulates around their organs (visceral) or in their hips, thighs, and legs (peripheral). The rs10195252 variant in the intergenic region between GRB14 and COBLL1 on chromosome 2 is one of the most replicated genetic determinants of this fat routing — and its effects are substantially stronger in women than men.

GRB14 (Growth Factor Receptor-Bound Protein 14) is an adaptor protein that acts as a braking mechanism on the insulin receptor¹¹ adaptor protein that acts as a braking mechanism on the insulin receptor
GRB14 binds to the activated insulin receptor and inserts its BPS domain as a pseudosubstrate inhibitor, blocking downstream signaling. Higher GRB14 expression in adipose tissue means weaker insulin signaling in that depot, which in turn affects how efficiently fat is stored and mobilized there. COBLL1 (Cordon-Bleu WH2 Repeat Protein-Like 1) is the neighboring gene and shares part of the regulatory landscape; it too is associated with leptin, central obesity, and fasting insulin.

The Mechanism

rs10195252 sits in the intergenic region between GRB14 and COBLL1 and functions as an expression quantitative trait locus (eQTL)²² expression quantitative trait locus (eQTL)
An eQTL is a genetic variant that controls how much mRNA a nearby gene produces, without changing the protein's amino acid sequence for GRB14 in adipose tissue. The T allele drives higher GRB14 expression, particularly in visceral adipose tissue, which suppresses insulin signaling in the belly and promotes a pattern where fat moves toward central compartments and away from peripheral depots. The C allele is associated with lower GRB14 expression, allowing more robust insulin signaling in visceral fat — which has the paradoxical effect of facilitating fat storage in peripheral depots (hips, thighs, lower limbs) while leaving central fat accumulation less hormonally supported.

This means the C allele shifts the body's default fat routing toward gynoid (peripheral/lower-body) distribution³³ gynoid (peripheral/lower-body) distribution
Named for the pattern more common in women; associated with higher hip-to-waist ratio and fat deposition in thighs, buttocks, and lower legs. The T allele does the opposite — it shifts fat toward the android (central, visceral) pattern. This explains why the T allele increases waist-hip ratio (WHR) while the C allele decreases it.

The Evidence

The foundational study is the 2010 GIANT consortium meta-GWAS of 77,167 individuals⁴⁴ meta-GWAS of 77,167 individuals
Analysis across 32 separate genome-wide association studies; rs10195252 reached p = 5.9 × 10⁻¹⁵ for WHR adjusted for BMI, which identified rs10195252 as one of 13 new loci for waist-hip ratio. The GRB14 locus showed marked sexual dimorphism — the effect was substantially stronger in women than men — consistent with estrogen's role in modulating insulin signaling in adipose depots. A subsequent larger meta-analysis of 224,459 individuals⁵⁵ larger meta-analysis of 224,459 individuals
Shungin et al. 2015; linked adipose tissue biology and insulin signaling directly to fat distribution genetics confirmed the locus among those most strongly linking adipose insulin biology to body fat distribution.

A key functional study by Gruber et al. 2022⁶⁶ Gruber et al. 2022
n = 2,860 subjects with metabolic phenotypes; 560 subjects with adipose tissue gene expression measurements demonstrated that the T allele at rs10195252 was significantly associated with increased GRB14 mRNA in visceral adipose tissue and that this visceral GRB14 expression fully mediated the association between rs10195252 and HbA1c — connecting the genetic variant to real-world glucose regulation through an adipose tissue molecular pathway. Carriers of the T allele also showed higher triglycerides, higher fasting plasma glucose, and lower HDL cholesterol.

The connection to lipedema — a condition of disproportionate lower-body and limb fat accumulation predominantly in women — was established by a UK Biobank GWAS of 24,450 cases⁷⁷ UK Biobank GWAS of 24,450 cases
Lörcher et al. 2022; GRB14/COBLL1 locus replicated in independent clinical lipedema cohort (130 cases); p = 2.3 × 10⁻³. The locus was associated specifically with leg fat percentage, independently of hip circumference — meaning the effect is not simply driven by large hips but by fat throughout the lower limbs. This finding directly implicates C-allele-driven peripheral fat routing in lipedema pathophysiology.

Practical Implications

For individuals carrying one or two copies of the C allele, the body's fat storage preference runs toward the lower limbs and hips. This does not cause lipedema on its own — lipedema is multifactorial — but it represents a significant component of the genetic predisposition. The insulin signaling pattern in visceral adipose may be more robust (lower GRB14 expression), but peripheral fat depots respond to insulin more readily, making them preferential storage sites.

Two actionable implications follow: First, interventions that transiently lower insulin (reducing carbohydrate intake, time-restricted eating) can partially redirect fat mobilization away from the peripheral depots where GRB14 expression is lower and insulin sensitivity is higher. Second, monitoring waist-hip ratio and lower-limb circumference provides more informative tracking data than scale weight alone, since weight loss may unevenly reduce peripheral fat stores.

The T-allele pattern (higher central fat tendency, higher GRB14 visceral expression) carries its own concern: association with higher HbA1c, triglycerides, and fasting insulin suggests elevated cardiometabolic risk independent of BMI.

Interactions

The GRB14/COBLL1 locus interacts with other fat distribution variants on chromosome 2 and overlapping GWAS signals. The nearby rs6738627 in COBLL1⁸⁸ rs6738627 in COBLL1
A second index SNP at this locus with partially independent effects on body fat percentage and leptin levels is separately associated with body fat percentage independently of BMI. Both rs10195252 and rs6738627 show overlapping metabolic associations (triglycerides, glucose, leptin), suggesting the entire locus regulates adipose tissue insulin signaling and fat partitioning as a functional unit.

Supervisor note — candidate compound interaction: The C allele at rs10195252 (peripheral fat routing) and the A allele at rs9939609 (FTO, increased adiposity/appetite) combine in a pattern where both fat volume and fat routing tilt unfavorably — higher total fat mass directed preferentially to limbs and lower body. Published evidence for this specific combination is not available, but both loci are independently established for fat distribution traits and the combined phenotype (excess peripheral fat mass) is clinically meaningful for lipedema risk assessment. A compound monitoring recommendation covering both variants would be appropriate if supported by future data.

The IL1RL1 gene¹¹ IL1RL1 gene
Interleukin-1 Receptor-Like 1, encoding the ST2 protein — the cell-surface receptor through which IL-33 activates mast cells, eosinophils, ILC2s, and Th2 lymphocytes is home to one of the most replicated loci in allergy genetics. Most people who have heard of ST2 genetics know about rs1420101 — the primary GWAS signal, located roughly 8.6 kilobases away on the same gene. But rs10208293 is something different: a second, statistically independent signal at the same locus that tracks a distinct biological mechanism and a specific clinical phenotype not captured by rs1420101 alone.

The IL-33/ST2 axis works like an epithelial alarm system. When airway or skin cells are damaged — by viruses, allergens, or pollutants — they release IL-33²² IL-33
A nuclear alarmin cytokine that, when released from damaged cells, binds to ST2 on innate lymphoid cells type 2 (ILC2s), mast cells, and eosinophils, triggering a rapid Th2 inflammatory cascade. The ST2 receptor exists in two forms: a membrane-bound signalling receptor that amplifies inflammation, and a soluble decoy receptor (sST2) that mops up free IL-33 and dampens the alarm. The ratio of membrane-bound to soluble ST2 determines how strongly any given tissue responds to an IL-33 signal. Both rs1420101 and rs10208293 influence this ratio — but at different regulatory elements and to different effect.

The Mechanism

rs10208293 sits at position 102,349,850 on chromosome 2 (GRCh38), within an intron of IL1RL1. Like most regulatory intronic variants, it is presumed to act through an expression quantitative trait locus (eQTL) mechanism — altering how the gene is spliced or expressed in specific cell types rather than changing the protein sequence. The A allele tags a haplotype that modulates the balance between transmembrane IL1RL1 isoforms and the soluble decoy sST2.

The key observation is that rs10208293 is statistically independent from rs1420101 — the two variants carry separate signals in conditional analyses, meaning both must be genotyped to fully characterise a person's IL1RL1 haplotype. Their effects on sST2 levels are not additive duplicates of each other; they reflect distinct molecular mechanisms at the same gene, likely involving different regulatory elements or alternative splicing events across different tissues.

The Evidence

The variant's clinical significance was established in two convergent lines of evidence. The landmark Ferreira et al. GWAS in Nature Genetics³³ Ferreira et al. GWAS in Nature Genetics analysed 360,838 participants and identified 136 independent risk variants for allergic disease (asthma, hay fever, and eczema considered jointly); rs10208293 emerged as an independent IL1RL1 signal in conditional analyses, confirming it is not simply a proxy for rs1420101.

The phenotypic specificity was worked out in a two-cohort meta-analysis by Savenije et al. (2014)⁴⁴ Savenije et al. (2014), which followed children in the PIAMA (n=2,007) and ALSPAC (n=7,247) birth cohorts. Crucially, this study distinguished wheezing phenotypes: early-transient, early-persistent, and late-onset wheeze. rs10208293 was one of exactly two IL1RL1 SNPs that associated specifically with late-onset wheeze — the phenotype that is most strongly predictive of persistent asthma in adulthood. This phenotypic specificity is clinically meaningful: children who develop wheeze only after age 4-6 years, rather than during toddlerhood, carry a different underlying immunological trajectory that rs10208293 appears to tag.

The biological link to airway inflammation is corroborated by the FeNO connection. Ketelaar et al. (2017)⁵⁵ Ketelaar et al. (2017) showed that circulating sST2 levels in preschool wheezers predict which children develop the eosinophilic subtype of asthma — defined by elevated FeNO⁶⁶ FeNO
Fractional exhaled nitric oxide, a non-invasive breath test that measures eosinophilic airway inflammation; levels above 25 ppb in adults and 20 ppb in children indicate eosinophilic inflammation (ATS/ERS guidelines) (AUC=0.65). Since rs10208293 is a regulatory variant affecting sST2 balance, carriers of the A allele have altered sST2 circulating levels that influence this eosinophilic trajectory.

Evidence from the Iranian population study⁷⁷ Iranian population study (126 asthmatics, 300 controls) further confirmed the AA genotype's association with asthma susceptibility (p=0.028). Population-specific data from Chinese Han children (Wu et al. 2021, PMID 34977013) showed an apparently different direction — the A allele appearing protective in that cohort — consistent with different linkage disequilibrium structure around the locus at low A allele frequency (~13%) in East Asian populations. This does not contradict the European GWAS data; it reflects a well-documented phenomenon where tagging SNPs for a causal variant show opposite directions when allele frequencies differ markedly across ancestries.

Practical Implications

For A allele carriers, the actionable insight centres on eosinophilic airway monitoring rather than general asthma management. The IL1RL1 locus specifically predicts the eosinophilic, Th2-driven subtype of airway disease — the subtype that responds to FeNO-guided treatment decisions and to biologics targeting the IL-33/ST2 pathway (itepekimab) or eosinophil biology (dupilumab, benralizumab, mepolizumab). Knowing that rs10208293 tags this phenotype specifically makes FeNO testing the highest-yield monitoring approach for A allele carriers with any history of wheeze or respiratory allergy.

Interactions

rs10208293 and rs1420101 are the two independent regulatory signals at the IL1RL1 locus. Their effects on sST2 are mechanistically distinct — carrying risk alleles at both represents a compounding of two separate derangements in the IL-33 alarm system. This is the interaction worth tracking in compound analysis.

Upstream, the IL33 gene⁸⁸ IL33 gene variant rs992969 determines how much IL-33 ligand is produced. A person carrying risk alleles at both IL33 (rs992969) and IL1RL1 (rs10208293) faces elevated ligand production meeting altered receptor regulation — a combined effect on the entire IL-33/ST2 signaling axis that neither variant predicts alone. The TSLP locus (rs1837253, rs3806933) acts upstream in the same Th2 pathway, and carriers of multiple allergy GWAS risk variants in this pathway have substantially higher cumulative risk than predicted by any single SNP.

Among the thousands of genetic variants linked to type 2 diabetes, very few are genuinely protective. The rs10305492 variant in the GLP-1 receptor gene¹¹ GLP-1 receptor gene
GLP1R encodes the receptor targeted by semaglutide (Ozempic/Wegovy) and liraglutide (Victoza/Saxenda) is one of them. This low-frequency missense variant (about 1.6% allele frequency in Europeans, rare or absent in other populations) substitutes alanine with threonine at position 316 in the receptor's fifth transmembrane domain. Carriers enjoy lower fasting glucose, reduced risk of type 2 diabetes, and protection against coronary heart disease -- but may respond differently to the very drugs that target this receptor.

The Mechanism

The A316T substitution sits in the fifth transmembrane helix²² fifth transmembrane helix
One of seven helices that span the cell membrane and form the receptor's signaling core of the GLP-1 receptor, a region critical for receptor activation. Functional studies in mice expressing the human A316T variant reveal that this change causes constitutive activation³³ constitutive activation
The receptor signals at a low level even without GLP-1 binding of the receptor at baseline. This means the receptor is partially "switched on" all the time, maintaining a tonic signal that improves fasting metabolic parameters. However, this same constitutive activity leads to receptor desensitization, which dampens responses to pharmacological GLP-1 receptor agonists⁴⁴ dampens responses to pharmacological GLP-1 receptor agonists
Drugs like semaglutide and liraglutide may have reduced effect because the receptor is already partially activated when they are administered.

The Evidence

The protective effect was first identified in a large exome chip meta-analysis⁵⁵ large exome chip meta-analysis
Wessel et al. Low-frequency and rare exome chip variants associate with fasting glucose and T2D susceptibility. Nature Comms, 2015 of 60,564 non-diabetic individuals, where the A allele was associated with lower fasting glucose (beta = -0.09 mmol/L per allele, P = 3.4 x 10^-12) and reduced T2D risk (OR 0.86, 95% CI 0.76-0.96, P = 0.010) in 16,491 cases and 81,877 controls. Notably, the variant was also associated with higher 2-hour glucose (beta = +0.16 mmol/L, P = 4.3 x 10^-4) and lower early insulin secretion, suggesting the protective effect operates through improved fasting state rather than enhanced meal-time response.

A subsequent therapeutic target validation study⁶⁶ therapeutic target validation study
Scott et al. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for CHD. Sci Transl Med, 2016 extended these findings to cardiovascular outcomes. In 61,846 coronary heart disease cases and 163,728 controls, the glucose-lowering allele was associated with CHD protection -- and the protective effect was larger than what would be predicted from glucose lowering alone, suggesting direct cardiovascular benefits of GLP-1R signaling.

In vivo functional profiling⁷⁷ In vivo functional profiling
In vivo functional profiling and structural characterization of the human GLP1R A316T variant. Sci Adv, 2024 in a knock-in mouse model confirmed that A316T causes constitutive receptor activation with improved fasting metabolic parameters but blunted responses to pharmacological GLP-1 receptor agonists. This is a critical finding for pharmacogenomics: the same variant that protects against diabetes may reduce the effectiveness of the drugs designed to mimic its natural ligand.

Practical Actions

If you carry the A allele, your natural GLP-1 receptor function is protective -- your fasting glucose tends to be lower and your cardiovascular risk is reduced compared to non-carriers. However, if you are prescribed a GLP-1 receptor agonist (semaglutide, liraglutide, exenatide, dulaglutide, or tirzepatide), your response may be attenuated because your receptor is already constitutively active. This does not mean these drugs won't work at all -- it means you may need different expectations for dose-response and should discuss your genotype with your prescriber.

Interactions

This variant interacts with rs3765467 (GLP1R R131Q), another missense variant in the same receptor that alters the extracellular binding domain. While A316T causes constitutive activation in the transmembrane domain, R131Q changes ligand binding in the extracellular domain. Carriers of both variants would have a GLP-1 receptor altered at two distinct functional regions, potentially compounding effects on both endogenous GLP-1 signaling and pharmacological response. No studies have yet characterized this combined genotype, but it represents a plausible compound pharmacogenomic interaction for GLP-1 receptor agonist therapy.

Lymphotoxin-alpha (LTα)¹¹ Lymphotoxin-alpha (LTα)
a homotrimeric or heterotrimeric cytokine of the TNF superfamily, secreted mainly by activated lymphocytes and NK cells is one of the founding members of the immune signaling family that includes TNF itself. Unlike TNF, which is broadly expressed by macrophages and adipocytes, LTα is produced predominantly by lymphocytes and has a distinct but overlapping set of receptors and biological roles. Its two receptors — TNFR1 and TNFR2 — are shared with TNF, but LTα also forms heterotrimers with lymphotoxin-beta (LTβ) to activate the LTβ receptor, which directs lymphoid organogenesis. LTα is essential for the normal development of lymph nodes, Peyer's patches, and other secondary lymphoid structures, and it drives innate immune responses against bacteria, viruses, and transformed cells.

The rs1041981 variant — historically called the TNFB*2 allele — substitutes asparagine for threonine at position 26 of the mature protein (position 60 in the precursor, after a 34-residue signal peptide is cleaved). This change falls in the N-terminal "stalk" region of the LTα subunit, which is involved in receptor binding and trimer stability, and the A allele frequency is approximately 35% globally²² A allele frequency is approximately 35% globally, making it one of the more common functional variants in the TNF/LTA chromosomal region at 6p21.33.

The Mechanism

LTα is synthesized as a 205-amino-acid precursor. After signal peptide cleavage at position 34, the mature 171-amino-acid protein assembles into trimers that bind TNFR1 and TNFR2. The Thr26Asn change (mature protein numbering) introduces an asparagine in a region that contacts receptor ectodomains. UniProt annotation (P01374) classifies this as a natural variant at precursor position 60³³ UniProt annotation (P01374) classifies this as a natural variant at precursor position 60, confirming the Asn substitution occurs in the trimer's receptor-binding interface area. The biological consequence is subtle rather than ablative — LTα-Asn26 is secreted normally and retains signaling function, but may alter binding affinity to TNFR1/TNFR2, modestly shifting the inflammatory set-point of cells responding to LTα. The rs1041981 A allele is in strong linkage disequilibrium with the adjacent intron variant rs909253 (r² ~0.92 in European populations), meaning the two frequently travel together on the same TNFB*2 haplotype block and their independent effects are difficult to fully disentangle.

The Evidence

The most quantitatively robust finding is in cancer susceptibility. A 2013 meta-analysis of 30 case-control studies covering 58,649 participants⁴⁴ 2013 meta-analysis of 30 case-control studies covering 58,649 participants
Huang et al., PLoS One found that the rs1041981 A allele conferred a statistically significant 15% elevation in cancer risk (OR 1.15, 99% CI 1.07–1.25, p < 0.0001). The association was seen across multiple cancer types, consistent with LTα's broad role in tumor immune surveillance through TNFR-mediated apoptosis and lymphocyte recruitment to tumor sites. A more targeted study in hepatocellular carcinoma (Alhelf et al., 2023, n = 317)⁵⁵ (Alhelf et al., 2023, n = 317) confirmed the A allele was independently associated with HCC risk in an Egyptian case-control study.

In the cardiovascular domain, results are mixed. A 2012 autopsy study of 1,503 consecutive cases⁶⁶ 2012 autopsy study of 1,503 consecutive cases
Ikeda et al., Atherosclerosis found that AA + CA carriers had significantly greater coronary stenosis severity than CC homozygotes (OR 1.54, 95% CI 1.17–2.01), a pathological measure of subclinical atherosclerotic burden. However, the large ISIS case-control study of 6,928 MI cases⁷⁷ ISIS case-control study of 6,928 MI cases
Clarke et al., PLoS Genetics 2006 found no significant association between LTA variants including rs1041981 and myocardial infarction occurrence, though higher CRP levels were seen in certain LTA haplotypes. This pattern — subclinical atherosclerosis association without a clear MI event signal — suggests rs1041981 may influence arterial inflammation and plaque development without necessarily precipitating acute coronary events.

For infectious disease, a 2017 study of Inuit populations⁸⁸ 2017 study of Inuit populations
Song et al., Scientific Reports found the A allele significantly associated with bronchitis risk, with the magnitude of risk modified by environment (westernized vs. rural lifestyle). A family-based analysis of 160 trio families⁹⁹ family-based analysis of 160 trio families
Boraska et al., Human Immunology 2009 found significant overtransmission of the A allele to type 1 diabetes-affected offspring (p = 1.1×10⁻⁴), consistent with LTα's established role in pancreatic islet inflammation. The variant also sits within the same LTA/TNF haplotype block studied extensively for autoimmune diseases including rheumatoid arthritis, celiac disease, and multiple sclerosis, though rs1041981 itself is primarily a tag SNP for this region rather than the primary functional driver in all contexts.

Practical Actions

The rs1041981 A allele operates as a moderate risk modifier across several domains — cancer surveillance, subclinical atherosclerosis, and respiratory infection vulnerability — rather than a single-disease variant. Its effect size in each domain is modest (OR ~1.15–1.54 depending on the outcome), which means it does not warrant alarm but does point to specific monitoring strategies that can reduce the probability of adverse outcomes.

For A allele carriers, the most actionable implications relate to cancer screening adherence, cardiovascular inflammation monitoring, and attention to respiratory health. LTα's role in lymphoid tissue development and tumor immune surveillance means the A allele's modest risk operates through immune-modulating pathways rather than direct mutagenesis.

Interactions

The rs1041981 A allele resides within the classic HLA class III region¹⁰¹⁰ HLA class III region
a gene-dense segment of chromosome 6p21.33 housing TNF, LTA, and numerous immune-regulatory genes in strong LD. The adjacent intronic variant rs909253¹¹¹¹ rs909253
a commonly studied LTA intronic SNP in the same TNFB haplotype block travels with rs1041981 in ~92% of European haplotypes. The TNF promoter variant rs1800629¹²¹² rs1800629
TNF -308 G>A, the most studied TNF pathway polymorphism is in the same chromosomal neighborhood and occasionally studied in combined haplotype analyses with LTA variants. A combined LTA/TNF haplotype carrying both inflammatory alleles may produce additive effects on cytokine tone, though published compound analyses are limited for this specific pair.